{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:14:23Z","timestamp":1787022863757,"version":"build-2736575974"},"reference-count":23,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2020,11,28]]},"DOI":"10.1536\/ihj.20-377","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T17:07:17Z","timestamp":1605200837000},"page":"1289-1293","source":"Crossref","is-referenced-by-count":2,"title":["Acute Myocardial Infarction in an Adolescent Receiving Anagrelide for Essential Thrombocythemia with Underlying Persistent Coronary Endothelial Dysfunction"],"prefix":"10.1536","volume":"61","author":[{"given":"Ryuhei","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodo","family":"Gatate","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumori","family":"Sujino","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Todo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Saitama Medical University International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Arber DA, Orazi A, Hasserjian R, <i>et al<\/i>. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med 2019; 381: 2135-44.","DOI":"10.1056\/NEJMcp1816082"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 2014; 40: 348-58.","DOI":"10.1055\/s-0034-1370794"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gugliotta L, Tieghi A, Tortorella G, <i>et al<\/i>. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res 2011; 35: 1557-63.","DOI":"10.1016\/j.leukres.2011.06.030"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Birgeg\u00e5rd G, Besses C, Griesshammer M, <i>et al<\/i>. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of anagrelide Efficacy and Long-term safety study. Haematologica 2018; 103: 51-60.","DOI":"10.3324\/haematol.2017.174672"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tortorella G, Piccin A, Tieghi A, <i>et al<\/i>. Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. Leuk Res 2015; 39: 592-8.","DOI":"10.1016\/j.leukres.2015.03.014"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tefferi A, Barbui T. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia 2013; 27: 1617-20.","DOI":"10.1038\/leu.2013.99"},{"key":"8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","year":"2008","unstructured":"8. De Stefano V, Za T, Rossi E, <i>et al<\/i>. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372-80.","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fu R, Zhang L, Yang R. Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. Br J Haematol 2013; 163: 295-302.","DOI":"10.1111\/bjh.12530"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Harrison CN, Bareford D, Butt N, <i>et al<\/i>. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352-75.","DOI":"10.1111\/j.1365-2141.2010.08122.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bildirici U, Celikyurt U, Ural E. Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female. Clin Cardiol 2009; 32: 104-5.","DOI":"10.1002\/clc.20426"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lata K, Madiraju N, Levitt L. JAK2 mutations and coronary ischemia. N Engl J Med 2010; 363: 396-7.","DOI":"10.1056\/NEJMc1003478"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med 1998; 244: 49-53.","DOI":"10.1046\/j.1365-2796.1998.00314.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cella G, Marchetti M, Vianello F, <i>et al<\/i>. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 2010; 104: 151-6.","DOI":"10.1160\/TH09-09-0663"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Tefferi A, Guglielmelli P, Larson DR, <i>et al<\/i>. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124: 2507-13; quiz 615.","DOI":"10.1182\/blood-2014-05-579136"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Gisslinger H, Gotic M, Holowiecki J, <i>et al<\/i>. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121: 1720-8.","DOI":"10.1182\/blood-2012-07-443770"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ahluwalia M, Donovan H, Singh N, Butcher L, Erusalimsky JD. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J Thromb Haemost 2010; 8: 2252-61.","DOI":"10.1111\/j.1538-7836.2010.03970.x"},{"key":"18","unstructured":"18. Mazzucconi MG, Redi R, Bernasconi S, <i>et al<\/i>. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004; 89: 1306-13."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Harrison CN, Campbell PJ, Buck G, <i>et al<\/i>. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.","DOI":"10.1056\/NEJMoa043800"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lin GM, Chao TY, Wang WB. Acute coronary syndromes and anagrelide. Int J Cardiol 2007; 117: e17-9.","DOI":"10.1016\/j.ijcard.2006.07.079"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Piccin A, Steurer M, Feistritzer C, <i>et al<\/i>. Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Transl Res J Lab Clin Med 2017; 184: 21-34.","DOI":"10.1016\/j.trsl.2017.02.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Johnston H, Majewski H, Musgrave IF. Involvement of cyclic nucleotides in prejunctional modulation of noradrenaline release in mouse atria. Br J Pharmacol 1987; 91: 773-81.","DOI":"10.1111\/j.1476-5381.1987.tb11275.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Prati F, Regar E, Mintz GS, <i>et al<\/i>. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010; 31: 401-15.","DOI":"10.1093\/eurheartj\/ehp433"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/6\/61_20-377\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T22:46:20Z","timestamp":1606517180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/6\/61_20-377\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-377","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,28]]}}}